The Prebiotic Potential of a Yeast Cell Wall Fraction Containing Mannooligosaccharides and β-glucans.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Mean daily rating of gastrointestinal symptoms
研究概览
简要总结
Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.
详细描述
Novel prebiotics with specific microbiome targets and without adverse gastrointestinal symptoms are needed for the exploration of health benefits. This is a 3-week, open-label pilot study designed to evaluate the effect of 15 g per day of yeast-derived mannooligosaccharides on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adults 50-99 years of age.
- •Able to provide written informed consent in English.
- •Willingness to complete all study procedures
- •Healthy or diagnoses with Parkinson's or multiple system atrophy
排除标准
- •Yeast allergy.
- •Self-reported kidney disease.
- •Elite athletes or long-distance runners.
- •Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit.
- •Current use of laxatives or antidiarrheal medications.
- •Use of other investigational products within 3 months of the screening visit.
- •Previously or currently being treated for any intestinal disease or condition, including IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer (self-report).
- •Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection)
- •Current cancer treatment
- •Currently pregnant
结局指标
主要结局
Mean daily rating of gastrointestinal symptoms
时间窗: 14 days
Change from baseline mean sum of daily mean rating from 0 (no symptom) to 3 (severe symptoms)
次要结局
未报告次要终点